Food-as-medicine is a science.
What’s happening: The UK-born nutrition company ZOE secured a $15M Series B extension from Coefficient Capital to fuel US expansion.
Data-hungry. With 100K+ members and $118M raised to date, ZOE uses at-home labs, CGMs, and a subscription app to deliver health-optimized diets.
Pairing regular retesting with gamified food scores, the platform’s data-driven recommendations aim to eliminate UPFs and reverse chronic disease.
Proof positive. Despite research affirming its methodology, ZOE has a retention problem — according to CEO Jonathan Wolf half of users churn within nine months.
Forced to restructure this spring, ZOE is now zeroing in on American diets and the >50% of US adults managing at least one condition for long-term growth.
Of note, while weight loss is a benefit, it’s not ZOE’s primary focus — instead it’s using real food to improve overall well-being, including mood, sleep, and energy.
Punchline: GLP-1s have risen so rapidly because Americans need help and value what works. But weight loss jabs can’t fix a bad diet, and ZOE believes it can.
